Personalized Progeroid Disease Treatment and Cardiovascular Risk Management System
Legal Citation
Summary of the Inventive Concept
A next-generation system for personalized treatment of progeroid diseases, leveraging genomics, proteomics, and customized combination therapies to predict and mitigate cardiovascular disease risk
Background and Problem Solved
The original patent addressed the treatment of progeroid diseases and conditions, but its combination therapies were limited to fixed dosages and lacked personalized approaches. The new inventive concept addresses these limitations by integrating genomics, proteomics, and simulation modeling to provide customized treatment plans and cardiovascular risk assessments
Detailed Description of the Inventive Concept
The system consists of three modules: a genomics module for identifying genetic mutations associated with progeroid diseases, a proteomics module for detecting aberrant lamin A protein levels, and a therapeutic module for administering customized combination therapies based on the identified mutations and detected protein levels. The system also includes a simulation engine for predicting the efficacy of various combination therapies on cellular aging and a database of known progeroid disease-causing mutations and therapeutic compounds. The kit for treating atherosclerosis includes a farnesyltransferase inhibitor, an mTOR inhibitor, and a guide for administering a customized combination therapy based on the subject's genetic profile and disease severity
Novelty and Inventive Step
The new inventive concept introduces a paradigm shift in personalized medicine by integrating genomics, proteomics, and simulation modeling to provide customized treatment plans and cardiovascular risk assessments. The inventive step lies in the combination of these modules and the simulation engine, which enables the prediction of treatment efficacy and the identification of novel therapeutic targets
Alternative Embodiments and Variations
Alternative embodiments may include the use of machine learning algorithms to analyze genomic and proteomic data, the integration of wearable devices for real-time monitoring of cardiovascular risk, or the development of companion diagnostics for identifying subjects most likely to benefit from customized combination therapies
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the pharmaceutical and biotechnology industries, particularly in the areas of personalized medicine, cardiovascular disease prevention, and progeroid disease treatment. The target market includes pharmaceutical companies, research institutions, and healthcare providers seeking to develop and implement personalized treatment approaches for progeroid diseases
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Medical biotechnology, specifically personalized medicine for progeroid diseases and cardiovascular risk management, requiring expertise in genetics, molecular biology, pharmacology, and computational modeling
Person of Ordinary Skill (PHOSITA) Profile
A medical researcher or clinical scientist with advanced degrees in molecular biology or genetics, familiar with combination therapies, genetic mutation analysis, and computational modeling of disease progression
Obviousness Rationale
A PHOSITA would recognize the PTD as a predictable extension of the source patent's combination therapy approach, leveraging standard techniques in personalized medicine to create a more comprehensive treatment system that integrates genomic analysis, protein detection, and customized therapeutic strategies.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,541 |
|---|---|
| Title | Combination therapies for treatment of laminopathies, cellular aging, and atherosclerosis |